The US Food and Drug Administration got right back into the novel drug approval game after a week off, giving its go-ahead to Ardelyx Inc.'s Ibsrela (tenapanor) for the treatment of irritable bowel syndrome with constipation (IBS-C). The Center for Drug Evaluation and Research has now approved 27 novel drugs in 2019.
Another notable approval went to a non-novel product:Xeris Pharmaceuticals Inc.'s Gvoke (glucagon) for the treatment of severe hypoglycemia
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?